9d • General discussion
THE “MAZ” STACK
- M = Metformin
- A = AOD-9604
- Z = Cagrilintide
Metformin
• Improves insulin sensitivity• Reduces hepatic glucose production• Activates AMPK (energy regulation pathway)• May blunt appetite in some individuals
AOD-9604 (HGH Fragment 176-191)
• Fragment of growth hormone• Studied for lipolysis (fat breakdown)• Does not significantly raise blood glucose like full GH• Primarily researched for stubborn fat reduction
Cagrilintide
• Long-acting amylin receptor agonist• Increases satiety signaling• Slows gastric emptying• Often discussed alongside GLP-1 agonists for dual appetite control
Why People Stack Them:
The theory behind MAZ:
- Metformin → improves metabolic efficiency
- AOD-9604 → supports fat mobilization
- Cagrilintide → suppresses appetite
So the stack aims to target:
- Appetite control
- Fat breakdown
- Insulin sensitivity
From multiple angles simultaneously.
Important Considerations
- Dosing varies widely in online discussions
- Potential side effects: GI distress, nausea, hypoglycemia risk (depending on combination and individual factors)
- Stacking appetite suppressants can increase nausea significantly
First — important context:
- Metformin is FDA-approved (prescription medication).
- AOD-9604 is a research peptide (not FDA-approved for fat loss).
- Cagrilintide is still in clinical development and not commercially approved in the U.S.
- Combining these is not an FDA-approved protocol and should only be done under medical supervision.
MAZ Stack Overview
M = Metformin
A = AOD-9604
Z = Cagrilintide
Typical Dose Ranges:
1️⃣ Metformin
Clinical ranges:
- 500 mg once daily → titrated
- Common therapeutic range: 1,000–2,000 mg/day divided doses
Titrated slowly to reduce GI side effects.
2️⃣ AOD-9604
Research ranges often cited:
- 250–500 mcg dailyUsually administered subcutaneously.
Human data is limited compared to GLP-1s.
3️⃣ Cagrilintide
In clinical obesity trials:
- Weekly dosing
- Doses studied ranged approximately 0.3 mg → 2.4 mg weekly (titrated)
Higher doses increase nausea risk.
What MAZ Is Trying to Do Mechanistically:
Component->Primary Target
Metformin->AMPK activation / insulin sensitivity
AOD-9604-> Lipolysis signaling
Cagrilintide-> Satiety and appetite suppression
It’s a 3-pathway metabolic approach:
- Improve insulin handling
- Mobilize fat
- Reduce intake
MAZ vs GLP-1 + Cagrilintide Stack:
GLP-1 options include:
- Semaglutide
- Tirzepatide
Mechanism Comparison:
MAZ Stack
- Mild to moderate appetite suppression
- Mild metabolic support
- Direct fat-fragment component (AOD)
- Generally less powerful than GLP-1 based stacks
GLP-1 + Cagrilintide
- Strong appetite suppression
- Significant delayed gastric emptying
- Central satiety amplification
- Clinically shown double-digit % weight loss in trials
GLP-1 + Cagrilintide = dual gut hormone signaling
MAZ = multi-pathway metabolic modulation
Strength Comparison:
Stack->Appetite Suppression->Fat Loss Potential->Nausea Risk
MAZ->Moderate->Mild–Moderate->Moderate
GLP-1 alone->Strong->Strong->Moderate–High
GLP-1 + Cagrilintide->Very Strong->Very Strong->High
MAZ Risks:
- Metformin → GI distress, B12 depletion long-term
- Cagrilintide → nausea, vomiting
- AOD → limited long-term human safety data
GLP-1 + Cagrilintide Risks
- Significant nausea if titrated too fast
- Risk of lean mass loss if protein/resistance training inadequate
- Gallbladder risk with rapid weight loss
Which Is “Stronger”?
For weight loss specifically:
GLP-1 + Cagrilintide is substantially more potent.
MAZ is generally discussed as:
- A milder metabolic stack
4
3 comments
THE “MAZ” STACK
skool.com/kristinas-peptide-junkies-24-4251
Advance your peptide research with precise, science-driven guidance, expert community talk, and access to vetted suppliers, promotions, and giveaways.
Leaderboard (30-day)
1
+7
2
+5
3
+4
4
+3
5
+3
Powered by